New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 12, 2012
05:35 EDTNKTRNektar to host conference call
Conference call to discuss Naloxegol study will be held on November 12 at 8:15 am. Webcast Link
News For NKTR From The Last 14 Days
Check below for free stories on NKTR the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 19, 2014
09:01 EDTNKTRNektar presents preclinical data on kappa opioid receptor
Nektar announced results from preclinical studies characterizing the analgesic profiles of a series of the company's internally-discovered oral, peripherally-acting kappa opioid receptor agonist molecules. The analgesic properties of kappa receptor agonism are well described in the medical literature.1,2 Kappa opioid receptors are expressed in the peripheral nervous system as well as in the central nervous system, and activation of these receptors at both sites has been shown to result in a reduction in pain and inflammation in a wide range of preclinical models. However, the therapeutic use of kappa receptor agonists has been limited because activation of these receptors in the CNS is associated with significant dysphoria and other unwanted side effects.
September 17, 2014
08:50 EDTNKTRNektar Movantik approval positive, says Roth Capital
Subscribe for More Information
September 16, 2014
14:33 EDTNKTRNektar price target raised to $20 from $18 at Brean Capital
Subscribe for More Information
13:22 EDTNKTRNektar approval improves risk/reward, says Piper Jaffray
Piper Jaffray says today's FDA approval of Movantik improves the risk/reward on shares of Nektar. Piper expects Movantik to be one of a series of successes for the company and reiterates an Overweight rating on the stock with a $20 price target. The firm says the post-marketing study required by the FDA to evaluate potential cardiovascular risks was expected.
13:17 EDTNKTRNektar up 3% after FDA approves Movantik for treatment of OIC
Subscribe for More Information
12:37 EDTNKTRNektar reports FDA approval of MOVANTIK for treatment of OIC
Nektar Therapeutics (NKTR) reported that partner AstraZeneca (AZN) announced that the FDA approved MOVANTIK tablets as the first once-daily oral peripherally-acting mu-opioid receptor antagonist medication for the treatment of opioid-induced constipation, or OIC, in adult patients with chronic, non-cancer pain. In line with the recommendation from the FDA Anesthetic and Analgesic Drug Products Advisory Committee that took place in June, AstraZeneca has agreed to conduct a post-marketing, observational epidemiologic cardiovascular safety study for MOVANTIK. MOVANTIK is expected to be available to patients in the first half of 2015. MOVANTIK is currently a schedule II controlled substance because it is structurally related to noroxymorphone. During the review of the New Drug Application, the FDA evaluated the abuse potential of MOVANTIK and the approved labelling indicates that MOVANTIK has no risk of abuse or dependency. AstraZeneca submitted a petition for the descheduling of MOVANTIK to the U.S. Drug Enforcement Administration, or DEA, in March 2012, which was accepted for review and will be considered by the DEA as part of the process for addressing the descheduling request.
10:19 EDTNKTRFDA approves Movantik with requirement for cardiovascular risk study
Subscribe for More Information
10:11 EDTNKTRNektar trading halted, pending news
08:00 EDTNKTRFDA PDUFA Date for Nektar and AstraZeneca''s Movantik is September 16, 2014

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use